Maheshwari Anshul sold $94K of SIBN

Maheshwari Anshul (Chief Op & Financial Officer) sold 5,049 shares of SI-BONE, Inc. (SIBN) at an average of $18.63 ($18.17–$19.50) across 3 trades over 2026-10-02 to 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maheshwari Anshul
Published Oct 6, 2026, 11:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The disclosed sale is modest in size relative to the insider's remaining holdings, suggesting limited market impact.

02

Market read

A small insider sell may cause slight short‑term pressure but is unlikely to drive significant price movement.

03

What to watch

Potential tax planning or portfolio rebalancing motives may drive the sale rather than operational concerns.

Relevance 2/10Novelty 2/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions; investors monitor them for signals about management confidence.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

Chief Operating & Financial Officer sold 5,049 shares for $94K via a 10b5-1 plan, reducing his stake to 218,235 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell.

Evidence & confidence

A C-suite insider sold shares worth under $100K, a modest amount that may be viewed as a slight negative signal but unlikely to move the stock dramatically.

Market effects

Minimal impact on the orthopedic device sector; no broader industry signal.

Limited to U.S. investors tracking SI-BONE.

Low; the transaction is company‑specific.

Counterpoint

The sale could be routine under a pre‑arranged 10b5‑1 plan, not reflecting any lack of confidence.

Key entities

  • Maheshwari Anshul

    Chief Operating & Financial Officer of SI‑BONE, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.